It is now clear that differential binding of ERα to chromatin is associated with clinical outcome in primary ERα-positive breast tumours[5], suggesting that changes in ERα binding mediates the altered gene expression program that dictates endocrine responsiveness and clinical outcome. The gene discussed is ESR1; the disease is breast neoplasm.